COMMUNIQUÉS West-GlobeNewswire

Evotec et Sanofi en négociations exclusives afin de créer, sous la direction d'Evotec, une plateforme R&D d'innovation ouverte dans les maladies infectieuses
08/03/2018
Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) Evotec et Sanofi en négociations exclusives afin de créer, sous la direction d'Evotec, une plateforme R&D d'innovation ouverte dans les maladies [...]
INNATE PHARMA: consolidated financial results for the year ended December 31, 2017
08/03/2018
2017: CLINiCAL PROGRESS, Portfolio expansion and financial strength create the foundation for future growth Cash, cash equivalents and financial assets [a] amounted to €176.6m (million euros) as of December 31, 2017 [...]
Innate Pharma : résultats financiers consolidés au 31 décembre 2017
08/03/2018
2017 : progrès cliniques, augmentation du portefeuille et solidité financière : les fondations de la croissance Trésorerie, équivalents de trésorerie et actifs financiersa s'élevant à 176,6m€ (million d'euros) au 31 [...]
G1 Therapeutics Announces Pricing of Offering of Common Stock
08/03/2018
RESEARCH TRIANGLE PARK, N.C., March 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,400,000 [...]
BriaCell Announces Proposed Investment by Leading Biotech Funds and Concurrent Non-Brokered Financing for aggregate gross proceeds of up to $4.8 Million
08/03/2018
BERKELEY, Calif. and VANCOUVER, British Columbia, March 07, 2018 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BriaCell Therapeutics Corp. ("BriaCell" or the "Company") ( [...]
Clearside Announces Pricing of Public Offering of Common Stock
08/03/2018
ALPHARETTA, Ga., March 07, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases [...]
Immuron Reports Positive Results in NASH Clinical Trial
08/03/2018
Headlines: First-In Class Anti-LPS Mechanism of Action confirmed for IMM-124E Results demonstrate excellent safety and tolerability Statistically significant reduction in serum endotoxin/ Lipopolysaccharide (LPS) levels [...]
Immuron Limited Issues Correction to Misleading Halt Announcement Headline
07/03/2018
MELBOURNE, Australia, March 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ: IMRN ) (the “Company”) wishes to correct a misleading halt announcement released over the wire yesterday. The misleading [...]
Psychemedics Corporation Announces Q4 and Year End Results
07/03/2018
ACTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD ) today announced fourth quarter and year-end financial results for the period ended December 31, 2017. The Company also announced a [...]
New Positive Data on Trogarzo™ (ibalizumab-uiyk) Injection and EGRIFTA® (tesamorelin for injection) Presented at 25th Conference on Retroviruses and Opportunistic Infections
07/03/2018
MONTREAL, March 07, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH ) today presented new results from additional analyses based on studies conducted with Trogarzo™ and EGRIFTA ® . The study [...]
De nouvelles données favorables concernant Trogarzo(MC) (ibalizumab-uiyk) injection et EGRIFTA(MD) (tésamoréline pour injection) présentées lors de la 25ième conférence sur les rétrovirus et infections opportunistes (CROI)
07/03/2018
MONTRÉAL, 07 mars 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH ) a présenté aujourd’hui de nouveaux résultats issus d’analyses additionnelles d’études sur Trogarzo MC et EGRIFTA MD . Les [...]
SeaSpine to Participate in the 38th Annual Cowen Healthcare Conference
07/03/2018
CARLSBAD, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE ), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced [...]
Zafgen to Present at Cowen 38th Annual Health Care Conference
07/03/2018
BOSTON, March 07, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq: ZFGN ), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]
CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update
07/03/2018
SOUTH SAN FRANCISCO, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX ), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of [...]
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
07/03/2018
BURLINGAME, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS ), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and [...]
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
07/03/2018
TUSTIN, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO ) (NASDAQ: CDMOP ), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by [...]
Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
07/03/2018
Successfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti™ dose Announced discovery of sex-based pharmacokinetic differences for Gimoti™ Met with FDA regarding NDA women-only [...]
Conatus Pharmaceuticals Reports 2017 Financial Results and Program Updates
07/03/2018
SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: CNAT ), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today [...]
Prothena to Participate in the Barclays Global Healthcare Conference
07/03/2018
DUBLIN, Ireland, March 07, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA ), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in [...]

Pages